Table 2.
Concordance of genomic alteration statuses between tumour tissue and NGS-based ctDNA analysis
| Author | Platform | N | Cancer | Alterations | Concordance | Sensitivity | Specificity |
| Bettegowda et al, 201424 |
Safe-SeqS | 206 | CRC | KRAS codon 12 to 13 | 95% | 87.2% | 99.2% |
| Bachet et al, 201825 | BPER | 330 | CRC | Extended RAS | 85.2% | 76.0% | 98.2% |
| Demuth et al, 201823 | Not specified | 28 | CRC | KRAS codon 12 to 13 | 79% | NA | NA |
| Wang et al, 201826 | Not specified | 56 | Gastro-oesophageal | HER2 amplification | 91.1% | 92% | 90.3% |
| Zill et al, 201527 | Guardant360 | 26 | Pancreatobiliary | KRAS, TP53, APC, FBXW7 and SMAD4 mutations | 97.7% | 92.3% | 100% |
| Schrock et al, 201828 | Not specified | 25 | GI | Not specified | 95% for mutations, 50% for amplifications | NA | NA |
CRC, colorectal cancer; ctDNA, circulating tumour DNA; GI, gastrointestinal; NA, not available.